CPL500036 · program
Alofropodect for Levodopa-induced dyskinesia in Parkinson's disease
Indications for CPL500036: Schizophrenia · Phase 2 Levodopa-induced dyskinesia in Parkinson's disease · Phase 2
Alofropodect (CPL'36), Celon Pharma's once-daily PDE10A inhibitor, for levodopa-induced dyskinesia (LID) in Parkinson's disease - the second indication. A multinational Phase 2 trial randomised 105 adults with moderate-to-severe LID 1:1:1 to 20 mg, 40 mg or placebo once daily for 4 weeks; both doses met the primary endpoint, improving the UDysRS total score versus placebo by 12.30 units (20 mg, p<0.001, Cohen's d 0.90) and 13.58 units (40 mg, p<0.001, d 1.00), with the UDysRS objective subscale improving from Day 7. The most common adverse event was mild-to-moderate somnolence; treatment-related discontinuations were 2.9% placebo, 11.1% 20 mg and 8.6% 40 mg, and one serious adverse event (moderate atrial fibrillation) occurred at 40 mg.
Development timeline
- metPhase 2 in levodopa-induced dyskinesia (n=105) met its primary endpoint: CPL'36 improved UDysRS total by 12.30 (20 mg) and 13.58 (40 mg) units vs placebo (both p<0.001).↗
- NCT05297201 completed (primary completion 2025-01-13, study completion 2025-01-27) with 105 participants enrolled.
- Trial (portion) completedPhase 2 LID study of CPL500036 (NCT05297201) completed
- Phase 2 randomised, placebo-controlled study NCT05297201 in levodopa-induced dyskinesia started (CPL500036 20 mg or 40 mg once daily vs placebo for 28 days; primary endpoint change in UDysRS total score at Week 4).
Readouts
- 2025-03-04ReportedTopline datametNCT05297201
Phase 2 in levodopa-induced dyskinesia (n=105) met its primary endpoint: CPL'36 improved UDysRS total by 12.30 (20 mg) and 13.58 (40 mg) units vs placebo (both p<0.001). ↗
Clinical trials in Levodopa-induced dyskinesia in Parkinson's disease
NCT0529720103PDE2020Phase 2Completedn=105
Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia
Formulations
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| Alofropodect oral capsule (20 mg / 40 mg once daily) 20 mg or 40 mg PO once daily in the morning for 28 days in both Phase 2 trials (schizophrenia NCT05278156; levodopa-induced dyskinesia NCT05297201). Phase 1 (NCT03873324): single ascending doses in 7 cohorts and 14-day multiple ascending doses in 4 cohorts, with placebo capsules; the CNS Drugs paper reports safety and dose-dependent exposure up to 100 mg daily in Phase 1. | Oral | Once daily | — |
Mechanism of action
Potent, selective inhibitor of phosphodiesterase 10A (PDE10A), a dual cAMP/cGMP phosphodiesterase expressed almost exclusively in striatal medium spiny neurons. Inhibiting PDE10A raises cyclic-nucleotide signalling in both the D1 (direct) and D2 (indirect) pathway neurons; Celon describes alofropodect as a second-generation, fast-dissociating ('fast-off') inhibitor with preferential modulation of D2- over D1-mediated striatal pathways, which it proposes as the reason it succeeded where earlier PDE10A inhibitors (e.g. TAK-063/balipodect, MK-8189/elpipodect) did not. In vitro it inhibited PDE10A with an IC50 of 1 nM and, in a 44-target radioligand panel, interacted only with the muscarinic M2 receptor (negative allosteric modulator, IC50 9.2 uM). It inhibited the hERG tail current at IC25 3.2 uM without cardiovascular effects in 3D cardiac spheroids or dog telemetry, elicited catalepsy in rats at 0.6 mg/kg, and did not cause hyperprolactinaemia or hyperglycaemia at doses up to 3 mg/kg.
| Target | Action | Affinity |
|---|---|---|
| PDE10AprimaryPDE10A | Inhibitor | IC50 1 nMⓘ |
← Full CPL500036 compound page (identity, identifiers, all indications)
Sources
- Matloka M, et al. A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects. Front Pharmacol. 2022;13:999685 — Frontiers in Pharmacology / PubMed
- NCT05297201 (03PDE2020) - Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia — ClinicalTrials.gov (U.S. National Library of Medicine)
- Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease (Celon Pharma, 2025-03-04, repost) — Celon Pharma S.A. (reposted by santelog.com)
- Wieczorek M, et al. CNS Drugs 2026 - full text (PK, adverse events, funding) — CNS Drugs (Springer) via PubMed Central